We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Emergent Biosolutions (EBS) Com Stk USD0.001

Sell:$46.65 Buy:$46.84 Change: $0.51 (1.10%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.51 (1.10%)
Prices delayed by at least 15 minutes | Switch to live prices |
Change: $0.51 (1.10%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Emergent BioSolutions Inc. is a life sciences company focused on providing civilian and military populations with a portfolio of preparedness and response products and solutions that address accidental, deliberate and naturally occurring public health threats (PHTs). The Company is focused on five PHT categories: Chemical, Biological, Radiological, Nuclear and Explosives (CBRNE); emerging infectious diseases (EID); travel health; emerging health crises; acute/emergency care; and contract development and manufacturing (CDMO). It operates through four business units, which includes three product business units: Vaccines, Devices, Therapeutics; and one services business unit: CDMO. The Company's contract development and manufacturing service offerings cover development services, drug substance manufacturing and drug product manufacturing across the pharmaceutical and biotechnology industries as well as the United States Government (USG) and non-Governmental organizations.

Contact details

400 Professional Dr Ste 400
United States
+1 (240) 6313200

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$2.50 billion
Shares in issue:
53.80 million
New York Stock Exchange
United States
US dollar

Key personnel

  • Fuad El-Hibri
    Executive Chairman of the Board
  • Robert Kramer
    President, Chief Executive Officer, Director
  • Richard Lindahl
    Chief Financial Officer, Executive Vice President, Treasurer
  • Adam Havey
    Chief Operating Officer, Executive Vice President
  • Katherine Strei
    Executive Vice President - Human Resources and Communications, Chief Human Resources Officer
  • Atul Saran
    Executive Vice President-Corporate Development, General Counsel, Corporate Secretary
  • Sean Kirk
    Executive Vice President - Manufacturing and Technical Operations
  • Karen Smith
    Executive Vice President, Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.